Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 18104

2.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
4.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
5.

Cytokine gene expression in peripheral blood mononuclear cells and alloreactivity in hematopoietic cell transplantation with nonmyeloablative conditioning.

Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Dickmeiss E, Vindeløv LL.

Biol Blood Marrow Transplant. 2006 Jan;12(1):48-60.

7.

Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.

Maloney DG.

Leuk Lymphoma. 2003;44 Suppl 3:S99-105. Review.

PMID:
15202532
8.

Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.

Kobbe G, Schneider P, Aivado M, Zohren F, Schubert D, Fenk R, Neumann F, Kronenwett R, Pape H, Rong A, Royer-Pokora B, Hildebrandt B, Germing U, Gattermann N, Heyll A, Haas R.

Exp Hematol. 2002 Nov;30(11):1346-53.

PMID:
12423689
9.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

10.

Non-myeloablative transplants for malignant disease.

Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH.

Hematology Am Soc Hematol Educ Program. 2001:375-91. Review.

PMID:
11722994
11.

Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.

Resnick IB, Shapira MY, Slavin S.

Transpl Immunol. 2005 Aug;14(3-4):207-19. Epub 2005 Apr 26. Review.

PMID:
15982565
12.

Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation.

Kraus AB, Shaffer J, Toh HC, Preffer F, Dombkowski D, Saidman S, Colby C, George R, McAfee S, Sackstein R, Dey B, Spitzer TR, Sykes M.

Exp Hematol. 2003 Jul;31(7):609-21.

PMID:
12842706
14.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

15.

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.

Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.

Biol Blood Marrow Transplant. 2000;6(3A):309-20.

PMID:
10905768
16.

Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.

Slavin S, Nagler A, Aker M, Shapira MY, Cividalli G, Or R.

Rev Clin Exp Hematol. 2001 Jun;5(2):135-46. Review.

PMID:
11486652
18.

Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.

Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.

Biol Blood Marrow Transplant. 2001;7(11):604-12.

19.
20.

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R.

Blood. 1998 Feb 1;91(3):756-63.

Items per page

Supplemental Content

Write to the Help Desk